Atricureincis A Global Medical Device Company Based In Masonohiospecializing In Surgical Treatments For Atrial Fibrillationafiband Left Atrial Appendagelaamanagementfounded In 2000 And Publicly Traded On Nasdaq Since 2005Atricure Employs Around 1 300 People And Aims To Reduce The Global Burden Of Afib Through Advanced Technologies The Company Offers A Range Of Products For Cardiac Surgeons And Electrophysiologistsincluding Surgical Ablation Systemslaa Management Devicesand Pain Management Solutionskey Offerings Include The Isolator Synergy Clampsatriclip Systemand Cryosphere Probedesigned For Both Open Heart And Minimally Invasive Proceduresatricure Serves Hospitals And Medical Professionals Worldwideemphasizing Clinical Education To Enhance Surgical Outcomeswith A Mission Focused On Patient Safety And Innovationatricure Reported Nearly $430 Million In Revenue For The 2024 Fiscal Year
